JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
NASDAQ · Pharmaceuticals · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 3, 2026
$235.67
· % 处于52周区间
· 高于低点
· 至高点
$128.8052周低点
$266.3852周高点
市值 (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
收入 (TTM)
$4.60B
JAZZ 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$235.67
市值 (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
收入 (TTM)
$4.60B
ROE (TTM)
22.1%
负债/权益 (MRQ)
0.9
52周区间
$129–$266
JAZZ 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 Jazz Pharmaceuticals plc - Ordinary Shares 公司概况（来自维基百科）
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Pharmaceuticals
员工2890
国家IE
10年表现 收入、净利润、利润率和每股收益趋势
收入$4.27B2016-12-31 → 2025-12-31
EPS$-5.842016-12-31 → 2025-12-31
净利率20.4%
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | JAZZ | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 16.15年均值 ≈-12.5 | ≈-12.5 | · | · | |
| P/S (TTM) | 3.3 | · | · | · | |
| 市净率 (MRQ) | 3.2 | · | · | · | |
| 股价/自由现金流 (TTM) | 9.6 | · | · | · | |
| 市现率 (TTM) | 9.2 | · | · | · | |
| 市净率（有形资产） (MRQ) | 19.8 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | JAZZ | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 19.5% | · | · | · | |
| 税前利润率 (TTM) | 15.8% | · | · | · | |
| 净利润率 (TTM) | 20.4% | · | · | · | |
| ROA (TTM) | 8.5% | · | · | · | |
| ROE (TTM) | 22.1% | · | · | · |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | JAZZ | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.9 | · | · | · | |
| 流动比率 (MRQ) | 1.8 | · | · | · | |
| 长期负债/股东权益 (MRQ) | 0.7 | · | · | · |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | JAZZ | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 4.9%5年均值 ≈13.0% | ≈13.0% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 5.3%5年均值 ≈10.8% | ≈10.8% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 12.5% | · | · | · | |
| EPS YoY | 41.8% | · | · | · | |
| Net Income YoY (净利润同比增长) | 35.0% | · | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | 13.1% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 20.2% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | JAZZ | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$1.5M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-1.6%
下次报告
十一月 03, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 3, 2026 | $5.71 | $6.30 | -9.4% |
| 2026年3月31日 | $6.34 | $4.66 | 36.1% | |
| 2025年12月31日 | $6.64 | $6.65 | -0.11% | |
| 2025年9月30日 | $8.13 | $6.04 | 34.7% | |
| 2025年6月30日 | $-8.25 | $-7.76 | -6.4% | |
| 2025年3月31日 | $1.68 | $4.75 | -64.6% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | · | 60,696,000 | 61,200,000 | 61,000,000 | · | 61,414,000 | 62,882,000 | 62,537,000 | · | 63,114,000 | 63,991,000 | 63,494,000 | · | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | · | 61,606,000 | 61,200,000 | 61,000,000 | · | 63,174,000 | 69,625,000 | 62,537,000 | · | 71,293,000 | 73,540,000 | 73,771,000 | · | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $74.10 | $72.29 | · | $65.18 | $61.12 | $67.75 | · | $69.01 | $60.94 | $58.65 | · | $55.44 | · | · | · | · | |
| Revenue / Share | $17.41 | $16.17 | · | $18.28 | $17.09 | $14.72 | · | $16.70 | $14.70 | $14.42 | · | $13.64 | $13.02 | $12.10 | · | $14.98 | |
| Cash Flow / Share | · | $6.18 | · | · | · | $7.05 | · | · | · | $4.27 | · | · | · | $4.35 | · | · | |
| Cash / Share | $25.00 | $29.41 | · | $21.83 | $19.62 | $30.22 | · | $36.70 | $21.96 | $22.90 | · | $21.22 | · | · | · | · | |
| EPS (TTM) | $14.63 | $0.11 | · | $-6.21 | $-6.87 | $7.36 | · | $7.08 | $5.80 | $4.83 | · | $0.85 | $-1.60 | $-2.57 | · | $-0.37 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.60B | $4.44B | · | $4.16B | $4.09B | $4.06B | · | $3.99B | $3.91B | $3.84B | · | $3.79B | $3.76B | $3.74B | · | $3.58B | |
| Net Income TTM | $941M | $29M | · | $-368M | $-405M | $482M | · | $463M | $395M | $331M | · | $80M | $-87M | $-156M | · | $-19M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | 16.5 | 1718.6 | · | -21.2 | -15.4 | 16.9 | · | 15.7 | 18.4 | 24.9 | · | 152.3 | -77.5 | -56.9 | · | -360.2 | |
| P/S | 3.4 | 2.7 | · | 1.9 | 1.6 | 1.9 | · | 1.7 | 1.7 | 2.0 | · | 2.1 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| EV / Revenue | 4.0 | 3.5 | · | 2.9 | 2.6 | 2.7 | · | 2.7 | 2.8 | 3.1 | · | 3.3 | · | · | · | · | |
| Earnings Yield | 6.1% | 0.06% | · | -4.7% | -6.5% | 5.9% | · | 6.3% | 5.4% | 4.0% | · | 0.66% | -1.3% | -1.8% | · | -0.28% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| 净收入 | $-356M | $560M | $415M | $-224M | $-330M |
| 稀释后每股收益 (EPS) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
此报表无数据
基本面数据不足，尚无法生成此报表。
此报表无数据
基本面数据不足，尚无法生成此报表。
机构持有人 (13F) 687 家申报者 · $15.8B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
687
持有价值
$15.8B
新仓位
138
已退出持仓
56
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 138 (+32 与上一季度对比) | 56 (-21 与上一季度对比) | 240 (+24 与上一季度对比) | 188 (+19 与上一季度对比) | +942K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $1438254453 | 5968603 | 9.11% | 股份 |
| FMR LLC | $1110709035 | 4609326 | 7.04% | 股份 |
| VANGUARD GROUP INC | $1005914140 | 5917142 | 6.37% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731636247 | 3036213 | 4.64% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $657763761 | 2729650 | 4.17% | 股份 |
| Capital World Investors | $650043082 | 2697610 | 4.12% | 股份 |
| FRANKLIN RESOURCES INC | $491639148 | 2040250 | 3.12% | 股份 |
| STATE STREET CORP | $481895662 | 1999816 | 3.05% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $412909300 | 1713592 | 2.62% | 股份 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394839917 | 1638544 | 2.50% | 股份 |
| Bank of New York Mellon Corp | $380253849 | 1578013 | 2.41% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $359935093 | 1522568 | 2.28% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $357440125 | 1483031 | 2.26% | 股份 |
| AMERIPRISE FINANCIAL INC | $292895571 | 1215523 | 1.86% | 股份 |
| JPMORGAN CHASE & CO | $276634191 | 1160786 | 1.75% | 股份 |
| BANK OF AMERICA CORP /DE/ | $273763940 | 1136091 | 1.73% | 股份 |
| CITADEL ADVISORS LLC | $242578716 | 1006676 | 1.54% | 股份 |
| Swedbank AB | $233281128 | 968092 | 1.48% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $192606598 | 799297 | 1.22% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $184072164 | 763880 | 1.17% | 股份 |
| UBS Group AG | $182381760 | 756865 | 1.16% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $165478678 | 686719 | 1.05% | 股份 |
| NORGES BANK | $158279458 | 656843 | 1.00% | 股份 |
| MORGAN STANLEY | $151734512 | 629680 | 0.96% | 股份 |
| Mariner, LLC | $146630968 | 608615 | 0.93% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $135442731 | 562073 | 0.86% | 股份 |
| Allianz Asset Management GmbH | $131345759 | 545071 | 0.83% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129891746 | 539037 | 0.82% | 股份 |
| NORTHERN TRUST CORP | $123222660 | 511361 | 0.78% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $111450794 | 462509 | 0.71% | 股份 |
| GMT Capital Corp | $109279895 | 453500 | 0.69% | 股份 |
| Boston Trust Walden Corp | $106779349 | 443123 | 0.68% | 股份 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105278106 | 436893 | 0.67% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103893734 | 431148 | 0.66% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $96439086 | 400212 | 0.61% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $95008929 | 394277 | 0.60% | 股份 |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $91259201 | 378715 | 0.58% | 股份 |
| Nuveen, LLC | $88051524 | 365405 | 0.56% | 股份 |
| Sofinnova Investments, Inc. | $88036221 | 365341 | 0.56% | 股份 |
| Polaris Capital Management, LLC | $79270937 | 328966 | 0.50% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $77695234 | 322427 | 0.49% | 股份 |
| GOLDENTREE ASSET MANAGEMENT LP | $70838675 | 294435 | 0.45% | 股份 |
| Qube Research & Technologies Ltd | $70056003 | 290725 | 0.44% | 股份 |
| GOLDMAN SACHS GROUP INC | $67434009 | 279844 | 0.43% | 股份 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66815854 | 277279 | 0.42% | 股份 |
| Quantinno Capital Management LP | $65906960 | 273506 | 0.42% | 股份 |
| BANK OF MONTREAL /CAN/ | $58329921 | 242063 | 0.37% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $55096752 | 228645 | 0.35% | 股份 |
| Tri Locum Partners LP | $53427868 | 221720 | 0.34% | 股份 |
| Invesco Ltd. | $50427310 | 209268 | 0.32% | 股份 |
激进投资者及 5%+ 股东 6 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 申报 | 2014年6月20日 | · | 初始申报 | · | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 申报 | 2013年3月12日 | · | 初始申报 | · | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 申报 | 2012年3月14日 | · | 初始申报 | 资本结构 | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 申报 | 2011年9月30日 | · | 初始申报 | · | SEC |
| Azur Pharma Limited | 2011年9月28日 | · | 初始申报 | 并购/出售 | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 2005年4月28日 | · | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 56 位内幕人士 · 18 位高管 · 20 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 2026年9月8日 S | 143394 | 0 | 1 | $-486060 |
| Philip L Johnson | EVP & Chief Financial Officer | 2026年6月30日 F | 56431 | 0 | 0 | $0 |
| Matthew P. Young | EVP & CFO | 2019年3月6日 S | 36200 | 0 | 0 | $0 |
| Daniel N Swisher JR | President and COO | 2023年3月5日 F | 55014 | 0 | 0 | $0 |
| Christopher J. Tovey | EVP, COO & Managing Director E | 2022年7月5日 M | 14663 | 0 | 0 | $0 |
| Russell J. Cox | EVP & COO | 2017年12月11日 M | 102821 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 2026年9月10日 S | 47671 | 0 | 14 | $-11500359 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026年9月8日 F | 23815 | 0 | 2 | $-1418523 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026年8月27日 M | 65686 | 0 | 7 | $-20411738 |
| Samantha Pearce | EVP, Chief Commercial Officer | 2026年8月5日 F | 47131 | 0 | 1 | $-1625977 |
| Patricia Carr | SVP, Chief Accounting Officer | 2026年3月9日 S | 6512 | 0 | 7 | $-2458091 |
| Kim Sablich | EVP, GM of U.S. | 2023年6月5日 D | 28478 | 0 | 0 | $0 |
| Finbar Larkin | SVP, Technical Operations | 2023年3月6日 M | 21779 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | EVP, US Commercial | 2020年3月12日 S | 22118 | 0 | 0 | $0 |
| Paul Treacy | SVP, Technical Operations | 2019年8月12日 S | 16418 | 0 | 0 | $0 |
| Iain Mcgill | SVP, Europe & Rest of World | 2019年3月5日 F | 24938 | 0 | 0 | $0 |
| Karen J Wilson | SVP, Finance & PAO | 2019年3月5日 F | 18385 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | EVP & General Counsel | 2019年2月27日 M | 39738 | 0 | 0 | $0 |
| Bruce C Cozadd | 董事 | 2026年9月1日 S | 351875 | 0 | 21 | $-27147106 |
| Patrick Kennedy | 董事 | 2026年8月31日 F | 6452 | 0 | 0 | $0 |
| Mark Douglas Smith | 董事 | 2026年8月31日 F | 9579 | 0 | 1 | $-266746 |
| Jennifer E. Cook | 董事 | 2026年8月31日 F | 10736 | 0 | 0 | $0 |
| Laura Hamill | 董事 | 2026年8月31日 F | 6832 | 0 | 0 | $0 |
| Heather Ann Mcsharry | 董事 | 2026年8月31日 F | 18199 | 0 | 2 | $-1089119 |
| Rick E Winningham | 董事 | 2026年8月31日 F | 9466 | 0 | 2 | $-1656873 |
| Patrick G. Enright | 董事 | 2026年8月31日 F | 21278 | 0 | 0 | $0 |
| Ted W Love | 董事 | 2026年8月31日 F | 2389 | 0 | 0 | $0 |
| Norbert G Riedel | 董事 | 2026年8月31日 F | 6923 | 0 | 1 | $-655680 |
| Seamus Mulligan | 董事 | 2026年8月5日 A | 1184633 | 0 | 0 | $0 |
| Anne Oriordan | 董事 | 2025年8月8日 F | 16500 | 0 | 0 | $0 |
| Peter Gray | 董事 | 2023年8月14日 S | 16068 | 0 | 0 | $0 |
| Catherine A. Sohn | 董事 | 2023年8月14日 S | 14868 | 0 | 0 | $0 |
| Elmar Schnee | 董事 | 2021年8月5日 S | 8270 | 0 | 0 | $0 |
| Paul L Berns | 董事 | 2021年8月5日 S | 8290 | 0 | 0 | $0 |
| Bryan C Cressey | 董事 | 2012年3月9日 S | 27631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | 董事 | 2011年3月10日 A | · | 0 | 0 | $0 |
| Alexander E Albert | 董事 | 2008年8月15日 A | · | 0 | 0 | $0 |
| Patel Jaimin | 董事 | 2007年8月15日 A | · | 0 | 0 | $0 |
| Kenneth W O'Keefe | · | 2025年12月2日 F | 25811 | 0 | 0 | $0 |
| Karen L. Smith | · | 2018年3月5日 F | 28474 | 0 | 0 | $0 |
| Jeffrey K Tobias | · | 2015年3月5日 F | 38484 | 0 | 0 | $0 |
| Fintan Keegan | · | 2014年7月8日 M | 31750 | 0 | 0 | $0 |
| Kathryn E Falberg | · | 2014年3月5日 F | 133387 | 0 | 0 | $0 |
| James C Momtazee | · | 2013年8月13日 S | 17315 | 0 | 0 | $0 |
| Carol A Gamble | · | 2012年3月9日 S | 32213 | 0 | 0 | $0 |
| Alan Sebulsky | · | 2012年3月9日 S | 54355 | 0 | 0 | $0 |
| Samuel D Colella | · | 2012年1月11日 M | 38347 | 0 | 0 | $0 |
| Michael W Michelson | · | 2012年1月11日 M | 13885 | 0 | 0 | $0 |
| Mark G. Eller | · | 2011年8月13日 M | 4151 | 0 | 0 | $0 |
| Michael A. Desjardin | · | 2011年8月13日 M | 14574 | 0 | 0 | $0 |
| Janne Lt Wissel | · | 2011年5月31日 J | 48544 | 0 | 0 | $0 |
| Joan Colligan | · | 2010年11月30日 J | 14424 | 0 | 0 | $0 |
| Robert M Myers | · | 2010年11月30日 J | 156898 | 0 | 0 | $0 |
| James B Tananbaum | · | 2010年8月25日 A | 21366 | 0 | 0 | $0 |
| Samuel R Saks | · | 2009年1月21日 A | 358868 | 0 | 0 | $0 |
| Matthew K Fust | · | 2008年11月28日 J | 58948 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 62 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IHE · iShares Trust | 3.45% | 232236 SH | 2026年9月11日 | 每日 |
| PJP · Invesco Exchange-Traded Fund Trust | 2.85% | 68707 SH | 2026年10月1日 | 每日 |
| XMMO · Invesco Exchange-Traded Fund Trust | 2.31% | 699006 SH | 2026年10月1日 | 每日 |
| PTH · Invesco Exchange-Traded Fund Trust | 1.69% | 26762 SH | 2026年10月1日 | 每日 |
| PILL · Direxion Shares ETF Trust | 1.25% | 1023 NS | 2026年7月31日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.98% | 4592 SH | 2026年10月1日 | 每日 |
| RFG · Invesco Exchange-Traded Fund Trust | 0.96% | 13808 SH | 2026年10月1日 | 每日 |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.79% | 61910 SH | 2026年8月19日 | 每日 |
| PDP · Invesco Exchange-Traded Fund Trust | 0.58% | 36818 SH | 2026年10月1日 | 每日 |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.58% | 14802 NS | 2026年7月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.54% | 27352 NS | 2026年7月31日 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trus... | 0.49% | 8679 SH | 2026年10月1日 | 每日 |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.41% | 101353 SH | 2026年8月19日 | 每日 |
| MIDU · Direxion Shares ETF Trust | 0.34% | 921 NS | 2026年7月31日 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.32% | 11363 SH | 2026年8月19日 | 每日 |
| VBR · VANGUARD INDEX FUNDS | 0.31% | 867777 SH | 2026年8月19日 | 每日 |
| VFMF · VANGUARD WELLINGTON FUND | 0.28% | 8083 SH | 2026年8月19日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.28% | 168574 NS | 2026年7月31日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.24% | 19561 SH | 2026年8月19日 | 每日 |
| IYH · iShares Trust | 0.23% | 34871 SH | 2026年9月11日 | 每日 |
| ESML · iShares Trust | 0.22% | 25740 SH | 2026年9月11日 | 每日 |
| DFAT · Dimensional ETF Trust | 0.22% | 123193 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.20% | 166548 SH | 2026年8月19日 | 每日 |
| SMMD · iShares Trust | 0.20% | 31945 SH | 2026年9月11日 | 每日 |
| RWK · Invesco Exchange-Traded Fund Trus... | 0.18% | 9978 SH | 2026年10月1日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.17% | 719903 SH | 2026年8月19日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.17% | 1366973 SH | 2026年8月19日 | 每日 |
| IWS · iShares Trust | 0.14% | 88598 SH | 2026年9月11日 | 每日 |
| WSML · iShares Trust | 0.13% | 3647 SH | 2026年9月11日 | 每日 |
| IWR · iShares Trust | 0.11% | 244305 SH | 2026年9月11日 | 每日 |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.09% | 3138 SH | 2026年10月1日 | 每日 |
| XT · iShares Trust | 0.09% | 13710 SH | 2026年9月11日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.08% | 147012 NS | 2026年7月31日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.08% | 45748 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.05% | 7084 NS | 2026年7月31日 | N-PORT |
| IUSG · iShares Trust | 0.04% | 55258 SH | 2026年9月11日 | 每日 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.04% | 36014 SH | 2026年8月19日 | 每日 |
| IWD · iShares Trust | 0.04% | 133301 SH | 2026年9月11日 | 每日 |
| DSI · iShares Trust | 0.04% | 8411 SH | 2026年9月11日 | 每日 |
| PRF · Invesco Exchange-Traded Fund Trust | 0.04% | 15040 SH | 2026年10月1日 | 每日 |
| IUS · Invesco Exchange-Traded Self-Inde... | 0.03% | 1369 SH | 2026年9月30日 | 每日 |
| DFAU · Dimensional ETF Trust | 0.03% | 13729 NS | 2026年7月31日 | N-PORT |
| DYNF · BlackRock ETF Trust | 0.02% | 39438 SH | 2026年9月11日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.02% | 467 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.02% | 2648 SH | 2026年9月11日 | 每日 |
| DFUS · Dimensional ETF Trust | 0.02% | 17349 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.02% | 81293 SH | 2026年9月11日 | 每日 |
| IWB · iShares Trust | 0.02% | 41012 SH | 2026年9月11日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 1892855 SH | 2026年8月19日 | 每日 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 9995 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 5021 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.02% | 13490 SH | 2026年8月19日 | 每日 |
| IWV · iShares Trust | 0.02% | 16075 SH | 2026年9月10日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.01% | 49429 SH | 2026年8月19日 | 每日 |
| OMFL · Invesco Exchange-Traded Self-Inde... | 0.01% | 1238 SH | 2026年10月1日 | 每日 |
| NEAR · iShares U.S. ETF Trust | 0.00% | 200000 SH | 2026年9月9日 | 每日 |
| IJH · iShares Trust | · | 2201423 SH | 2026年9月11日 | 每日 |
| IJK · iShares Trust | · | 363871 SH | 2026年9月11日 | 每日 |
| XJH · iShares Trust | · | 8572 SH | 2026年9月8日 | 每日 |
| ISCB · iShares Trust | · | 2820 SH | 2026年9月11日 | 每日 |
| ISCV · iShares Trust | · | 13894 SH | 2026年9月11日 | 每日 |
| SMMV · iShares Trust | · | 4635 SH | 2026年8月19日 | 每日 |
JAZZ 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 26 位分析师
买入
中位数目标
$300.00
+27.3%
7 26.9%
强烈买入
17 65.4%
买入
2 7.7%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
22 位分析师 · 2026-10-03平均目标 $294.27 +24.9%
现在
当前价格 $235.67
最低$225.00
平均值$294.27
最高$337.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 3, 2026 申报